Human renal UOK130 tumor cells: A drug resistant cell line with highly selective over-expression of glutathione S-transferase-π isozyme

European Journal of Pharmacology

Volumn 568, Issue 1-3, 2007, Pages 61-67

  Wang, Wei ^a   Liu, Guangxian ^a   Zheng, Jiang ^a,b  

^a NORTHEASTERN UNIVERSITY   (United States)

^b SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

Author keywords

Cisplatin resistance; Glutathione S transferase; Haloenol lactone

Indexed keywords

CHLORAMBUCIL; CISPLATIN; COMPLEMENTARY DNA; GLUTATHIONE; GLUTATHIONE S TRANSFERASE MU; GLUTATHIONE TRANSFERASE ALPHA; GLUTATHIONE TRANSFERASE P1; HALOENOL LACTONE DERIVATIVE; ISOENZYME; LACTONE DERIVATIVE; MELPHALAN; POLYCLONAL ANTIBODY; TRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EXPOSURE; GENE OVEREXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MODEL; PRIORITY JOURNAL;

4-BUTYROLACTONE; ANTINEOPLASTIC AGENTS; CARCINOMA, RENAL CELL; CELL LINE, TUMOR; CHLORAMBUCIL; CISPLATIN; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; GLUTATHIONE; GLUTATHIONE S-TRANSFERASE PI; HUMANS; ISOENZYMES; KIDNEY NEOPLASMS; MELPHALAN; TRANSFECTION;

EID: 34347206342     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejphar.2007.04.021     Document Type: Article

References (17)

1. Go R.S., and Adjei A.A. Review of the comparative pharmacology and clinical activity of cisplatin and carboplatin. J. Clin. Oncol. 17 (1999) 409-422
2. Gottesman M.M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 53 (2002) 615-627
3. Habig W.H., Pabst M.J., and Jakoby W.B. Glutathione S-transferases. The first enzymatic step in mercapturic acid formation. J. Biol. Chem. 249 (1974) 7130-7139
4. Kartalou M., and Essigmann J.M. Mechanisms of resistance to cisplatin. Mutat. Res. 478 (2001) 23-43
5. Masters R.W.J. Animal Cell Culture: a Practical Approach (2000), Oxford University Press
6. Morgan A.S., Ciaccio P.J., Tew K.D., and Kauvar L.M. Isozyme-specific glutathione S-transferase inhibitors potentiate drug sensitivity in cultured human tumor cell lines. Cancer Chemother. Pharmacol. 37 (1996) 363-370
7. O'Brien M., Kruh G.D., and Tew K.D. The influence of coordinate overexpression of glutathione phase II detoxification gene products on drug resistance. J. Pharmacol. Exp. Ther. 294 (2000) 480-487
8. Perez R.P. Cellular and molecular determinants of cisplatin resistance. Eur. J. Cancer 34 (1998) 1535-1542
9. Shen H., Kauvar L., and Tew K.D. Importance of glutathione and associated enzymes in drug response. Oncol. Res. 9 (1997) 295-302
10. Tew K.D. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res. 54 (1994) 4313-4320
11. Tew K.D., and Ronai Z. GST function in drug and stress response. Drug Resist. Updat. 2 (1999) 143-147
12. Townsend D., and Tew K. Cancer drugs, genetic variation and the glutathione-S-transferase gene family. Am. J. Pharmacogenomics 3 (2003) 157-172
13. Townsend D.M., and Tew K.D. The role of glutathione-S-transferase in anti-cancer drug resistance. Oncogene 22 (2003) 7369-7375
14. Townsend D.M., Tew K.D., and Tapiero H. The importance of glutathione in human disease. Biomed. Pharmacother. 57 (2003) 145-155
15. Zheng J., Mitchell A.E., Jones A.D., and Hammock B.D. Haloenol lactone is a new isozyme-selective and active site-directed inactivator of glutathione S-transferase. J. Biol. Chem. 271 (1996) 20421-20425
16. Zheng J., Wurz G.T., Cadman T.B., Degregorio M.W., Jones A.D., and Hammock B.D. Haloenol lactone: a new synergist of chemotherapy in vitro. Biochem. Biophys. Res. Commun. 241 (1997) 13-17
17. Zheng J., Liu G., Tozkoparan B., and Wen D. Mechanistic studies of inactivation of glutathione S-transferase Pi isozyme by a haloenol lactone derivative. Med. Chem. 1 (2005) 191-198